Florian S.
- Country
- Germany
- Department
- Klinik für Kinderheilkunde
Research Overview
- Evaluation of Long-term Safety and Efficacy of Tezacaftor, Deutivacaftor, and Vanzacaftor Combination Therapy in Patients with Cystic Fibrosis
- Long-term Safety and Efficacy Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Aged 12 Months and Older
- Phase 3 Open-Label Study on Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Aged 12 to <24 Months
Data & Insights
Has run more than one trial at 10 of 82 partner sites.
Specializations
Pediatric Cystic Fibrosis Research
This investigator specializes in studying innovative treatments for cystic fibrosis in pediatric populations, with particular focus on patients from infancy through adolescence. Their research encompasses age groups ranging from 12 months to 11 years.
- Infant and toddler CF treatment (12-24 months)
- Early childhood interventions (2+ years)
- Pre-adolescent care approaches
Clinical evaluations focus on age-specific therapeutic responses and safety profiles in young CF patients.
Novel Therapeutic Combinations
The investigator conducts research on advanced combination therapies for cystic fibrosis, including innovative drug combinations such as elexacaftor/tezacaftor/ivacaftor and vanzacaftor/tezacaftor/deutivacaftor.
- Triple combination treatments
- Long-term therapeutic efficacy
- Novel drug formulations
Research encompasses comprehensive evaluation of therapeutic safety and tolerability profiles.
Long-term Treatment Outcomes
Specialized focus on longitudinal studies examining the extended effects and safety of CF treatments across different age groups and therapeutic approaches.
- Extended safety monitoring
- Treatment durability assessment
- Long-term efficacy evaluation
The research emphasizes continuous monitoring of treatment outcomes and safety parameters in CF patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.